Ra Pharmaceuticals Announces Proposed Public Offering of Common Stock
February 13 2018 - 5:44PM
Business Wire
Ra Pharmaceuticals, Inc. (NASDAQ:RARX) (“Ra Pharma”) today
announced that it intends to offer and sell, subject to market and
other conditions, $50 million of its common stock in an
underwritten public offering. Ra Pharma expects to grant the
underwriters a 30-day option to purchase up to $7.5 million of
additional shares of its common stock.
Credit Suisse, Jefferies, and BMO Capital Markets are acting as
joint book-running managers for the offering. SunTrust Robinson
Humphrey is acting as lead manager.
Ra Pharma intends to use the net proceeds from the offering, in
addition to our existing cash resources, to fund its Phase 2 trial
for RA101495 for gMG, other pipeline programs, and for working
capital and general corporate purposes.
The securities described will be offered by Ra Pharma pursuant
to a shelf registration statement on Form S-3 (No. 333-221266),
including a base prospectus. The securities will be offered only by
means of a prospectus. A preliminary prospectus supplement related
to the offering and a final prospectus related to the offering will
be filed with the SEC and will be available on the SEC’s website
located at www.sec.gov. Copies of the preliminary prospectus
supplements and the accompanying prospectuses relating to the
securities being offered may also be obtained, when available,
from: Credit Suisse Securities (USA) LLC, Attn: Prospectus Dept.,
One Madison Avenue, New York, NY 10010, by telephone at 800-
221-1037 or by email at newyork.prospectus@credit-suisse.com;
Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520
Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at
877-547-6340 or by email at Prospectus_Department@Jefferies.com; or
BMO Capital Markets Corp., Attention: Equity Syndicate Department,
3 Times Square, New York, NY 10036, telephone: (800) 414-3627,
email: bmoprospectus@bmo.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Ra Pharmaceuticals
Ra Pharmaceuticals is a clinical stage biopharmaceutical company
focusing on the development of next-generation therapeutics for
complement-mediated diseases. The Company discovers and develops
peptides and small molecules to target key components of the
complement cascade.
Forward-Looking Statement
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including, but not limited to, statements regarding the
completion and anticipated proceeds of the proposed offering. All
such forward-looking statements are based on management's current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties related
to fluctuations in our stock price, changes in market conditions
and satisfaction of customary closing conditions related to the
public offering, as well as the other factors discussed in the
“Risk Factors” section in Ra Pharma’s most recently filed Annual
Report on Form 10-K, as well as other risks detailed in Ra Pharma’s
subsequent filings with the Securities and Exchange Commission.
There can be no assurance that Ra Pharma will be able to complete
the proposed public offering on the anticipated terms. All
information in this press release is as of the date of the release,
and Ra Pharma undertakes no duty to update this information unless
required by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180213006670/en/
Investors:Argot PartnersNatalie Wildenradt,
646-681-8192natalie@argotpartners.comorMedia:Argot PartnersDavid
Rosen, 212-600-1902david.rosen@argotpartners.com
Ra Pharmaceuticals (NASDAQ:RARX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ra Pharmaceuticals (NASDAQ:RARX)
Historical Stock Chart
From Apr 2023 to Apr 2024